Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 22, 2011

CDI to Supply iPSC-Derived Human Heart Cells for Roche's Drug Development Efforts

  • Cellular Dynamics International (CDI) and Roche report the completion of a two-year collaboration intended to substantiate the ability of CDI's iCell® Cardiomyocytes to assess potential cardiotoxic effects of drug candidates in development. The companies transitioned to a standard supply agreement under which iCell Cardiomyocytes will be incorporated into Roche's drug development decision-making process.

    "CDI and Roche have developed and demonstrated, respectively, a more efficient tool to reveal potential cardiotoxicity in their drug development candidates,” says Chris Parker, chief commercial officer of CDI. iCell Cardiomyocytes are produced from induced pluripotent stem cell (iPSC)-derived human heart cells.

    CDI and Roche initiated their collaboration in March 2009 to interrogate CDI's iCell Cardiomyocytes against a well-categorized compound reference set. The goal was to test the ability of the cardiomyocytes to predict drug-induced, potentially life-threatening cardiac arrhythmias.

    The studies included longitudinal genetic and molecular characterizations of the cardiomyocytes and assessment of their performance across a variety of testing platforms.  Multiple publications based on this research are being prepared for submission to peer-reviewed journals, the companies report.

Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »